Cioli D
Institute of Cell Biology of National Research Council, 43 Viale Marx, 00137 Rome, Italy.
Parasitol Today. 1998 Oct;14(10):418-22. doi: 10.1016/s0169-4758(98)01323-4.
No major changes have occurred during the past 20 years regarding the therapeutic tools available to the clinician for the treatment of schistosomiasis. If anything, the two drugs (oxamniquine and metrifonate) that are valuable alternatives to the drug of choice (praziquantel) have become more difficult to procure in some African countries. Here, Donato Cioli summarizes some of the most recent and interesting laboratory studies on potential antischistosomal compounds, and then reviews recent developments related to the mechanism of action of praziquantel and to the possible emergence of praziquantel-resistant schistosomes.
在过去20年里,临床医生用于治疗血吸虫病的治疗手段没有发生重大变化。要说有什么变化的话,作为首选药物(吡喹酮)的两种有价值替代药物(奥沙尼喹和敌百虫)在一些非洲国家更难获得了。在此,多纳托·乔利总结了一些关于潜在抗血吸虫化合物的最新且有趣的实验室研究,然后回顾了与吡喹酮作用机制以及吡喹酮抗性血吸虫可能出现相关的最新进展。